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 SUMMARY 
Gene therapy is a promising therapeutic strategy for gliomas, which are 
incurable by conventional approaches. The success of gene therapy is greatly 
dependent on delivery vectors. In the current study, we investigated the 
feasibility of using insect baculovirus as a gene delivery vector for glioma 
therapy. A glial-specific promoter was created by addition of a cytomegalovirus 
(CMV) enhancer upstream to a glial fibrillary acidic protein (GFAP) promoter. 
This expression cassette showed a high level expression of reporter genes in 
glioma cells in the context of baculovirus. The transgene expression level was 
further improved by flanking the expression cassette with inverted terminal 
repeats from adeno-associated virus. When therapeutic gene encoding 
diphtheria toxin A-chain was used, the inhibition of glioma cell growth was 
demonstrated in cell lines and in a rat C6 glioma xenograft model. RNA 
interference mediated by a recombinant baculoviral vector with a hybrid 
promoter (CMV enhancer/H1 promoter) was also studied and an effective 
knockdown of target gene expression was observed. These results show that 
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1.1 Gliomas: the terminator 
Gliomas are a collection of tumors that mainly originate from transformed 
glial cells, the supporting cells in the central nervous system (CNS; Holland, 
2000). Although the incidence is about 3 per 100000 people per year 
(DeAngelis, 2001), gliomas remain among the most devastating forms of 
human cancers. According to their malignancy, gliomas are clinically divided 
into four grades, among which grade 4 glioblastoma multiforme (GBM) 
accounts for half of all brain tumors and is the most invasive and aggressive 
form. Conventional therapeutic approaches such as surgery, chemotherapy, 
and radiotherapy, though progressing well in the past few decades, are still not 
able to effectively cure GBM, and most patients die 12-18 months (Surawicz et 
al., 1998) after diagnosis. The reason for the failure of treatment is inherent to 
the properties of gliomas, which are “multiforme” grossly, microscopically and 
genetically. In addition, gliomas are highly proliferative, highly vascularized, 
and aggressively infiltrative into the brain (Holland, 2000). Gliomas have also 
evolved a mechanism to escape from immune surveillance (Sikorski et al., 
2005). The outcome of surgery is often unsatisfactory, because it is difficult to 
completely dissect the tumors and the surgical operations in the brain often 
result in neurological complication. For the radiotherapy, the radiation dose 
required to kill gliomas is much higher than can be tolerated by normal brain 
tissues, and increased radiation dose is always associated with the occurrence 
of undesirable tissue damage. The failure of chemotherapy results partially 
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from the blood brain barrier (BBB), which hinders the transport of many 
chemical drugs, and thus makes it difficult to achieve an effective drug 
concentration in the brain to kill the glioma cells. Moreover, the appearance of 
chemo-resistant glioma cells makes it more difficult to treat. 
 
1.2 Glioma gene therapy: a novel strategy  
Because of the poor outcome of conventional approaches, great 
expectation has been set on novel therapeutic strategies such as gene therapy 
for the treatment of gliomas. Initially discussed during the 1960s and the 1970s 
(Friedmann, 1992), gene therapy is defined as the correction of missing genes, 
replacement of defective genes, removal or down regulation of abnormal 
genes. The inherited single gene disorder was the initial target of gene therapy, 
and evidence has accumulated that it can be used for the treatment of various 
diseases including hemophilia (Walsh, 2003), lysosomal storage disorders 
(Cheng et al., 2003), severe combined immunodeficiency (Gaspar et al., 2003), 
diabetes mellitus (Yechoor et al., 2005), cancer (McNeish et al., 2004), etc. 
Since the first gene therapy clinical trial for patients with gliomas was carried 
out more than a decade ago (Oldfield et al., 1993), many therapeutic 
modalities for gliomas have been proposed and investigated (Barzon et al., 
2006; Pulkkanen et al., 2005), among which are suicide gene therapy, genetic 
immunotherapy, tumor suppressor gene or oncogene approaches, and 
anti-angiogenesis gene therapy. 
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Suicide gene therapy is one of the commonly employed therapeutic 
approaches, accounting for 73% of the approved glioma gene therapy clinical 
trials (Barzon et al., 2006). As an attractive candidate for suicide gene therapy, 
the diphtheria toxin A-chain (DTA) gene has been extensively studied by 
several groups (Ayesh et al., 2003). Secreted by Corynebacterium diphtheriae 
as a precursor polypeptide, diphtheria toxin is composed of two fragments, the 
A and B chains. The B chain contains a binding domain which interacts with 
the receptors present on the surface of most eukaryotic cells and facilitates the 
cell uptake of the A chain into cytoplasm (Collier, 1975). Once inside the 
cytoplasm, the A chain will catalyze the ADP-ribosylation of diphthamide 
residue present in the eukaryotic elongation factor 2, which lead to inhibition of 
host cell protein synthesis and eventually result in the cell death (Choo et al., 
1994; Sandvig et al., 1992). Only a low concentration of DTA is required to 
cause cell death through a cell cycle-independent pathway (Yamaizumi et al., 
1978; Rodriguez et al., 1998).Thus, the DTA gene is superior to other 
candidate genes such as herpes simplex virus thymidine kinase (HSV-tk) gene, 
which requires administration of prodrugs and whose efficacy is often 
undermined by the low prodrug concentration achieved within the glioma cells 
in the brain. In addition, the DTA gene, encoding DTA, but not DTB, has 
already been cloned and engineered for expression in mammalian cells. 
Without the B chain, DTA released after cell death is unable to enter the nearby 
cells, thus preventing unwanted toxicity to normal tissues. 
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The use of RNA interference (RNAi) technique for glioma gene therapy is 
another recently developed strategy. RNAi was first described in C. elegans as 
a response to exogenous double-stranded RNA (Fire et al., 1998) and has 
subsequently been demonstrated in diverse eukaryotes such as insects, plants, 
fungi, and vertebrates. As a highly specific posttranscriptional gene silencing, 
RNAi is a powerful tool for functional genomic study, generating animal models, 
as well as in the treatment of many diseases such as viral infections and 
cancer. (Novina et al., 2004; Pardridge, 2004; Spankuch et al., 2005). The use 
of RNAi-based approaches for glioma therapy has been summarized in a 
recent review (Mathupala et al., 2006). Since the activation or over-expression 
of various genes related to cell-adhesion/motility and invasiveness, growth 
factors and/or their receptors is usually associated with the development of 
gliomas (Mathupala et al., 2006; Barker et al., 1995), knockdown the 
expression of these molecules such as vascular endothelial growth factor 
(VEGF; Tao et al., 2005), telomerase (Pallini et al., 2006), or epidermal growth 
factor receptor (EGFR; Kang et al., 2006; Saydam et al., 2005), could be an 
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1.3 Baculovirus: an emerging vector for gene therapy 
It is impossible to obtain success in gene therapy without effective gene 
delivery systems that can achieve high levels of therapeutic gene expression 
in targeted cells. Gene delivery vectors can be classified into viral and 
non-viral vectors. Non-viral gene delivery systems include: cationic polymer 
complexes (De Smedt et al., 2000), liposomes (Simoes et al., 2005), micelles 
(Adams et al., 2003) and nanoparticles (Panyam et al., 2003). Tremendous 
efforts have been made in the study of non-viral vectors, for several reasons. 
First, compared with viral vectors, non-viral vectors are less likely to induce an 
immune response and thus can be administered repeatedly to the patient 
without causing severe adverse effects or being neutralized by preexisting 
antibodies. Secondly, they are relatively easily manufactured as 
pharmaceutical products. However, the low transfection efficiency of non-viral 
vectors remains a notorious obstacle that needs to be overcome before use in 
clinical application. In contrast, high transduction efficiency is a distinct 
property of viral vectors such as retrovirus (Weber et al., 2001), adenovirus 
(McConnell et al., 2004), adeno-associated virus (Conlon et al., 2004), herpes 
simplex virus type 1 (Epstein et al., 2005), or lentivirus (Copreni et al., 2004). 
Viruses have evolved smart mechanisms to enter host cells and utilize the host 
cells’ machinery to survive. Owing to these mechanisms, which confer the viral 
vectors’ incomparably high transduction efficiency, viral vectors remain 
predominant in gene therapy clinical trials. However, the application of viral 
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vectors is also hindered by several shortcomings, including limited 
DNA-carrying capacity, insertional mutagenesis and immunogenicity. The 
death of a teenage from an immune reaction to the adenovirus vector during 
the clinical trial carried out at the University of Pennsylvania presents an 
example of the problems with viral vectors, one which even caused a setback 
in the gene therapy researches (Check, 2005).  
Recently, the baculovirus (Autographa californica multiple 
nucleopolyhedrovirus) based vectors, traditionally used as biopesticides 
(Tomalski et al., 1991) have emerged as novel gene delivery vectors with 
many attractive features (Ghosh et al., 2002; Kost et al., 2005). Firstly, 
baculovirus has an excellent biosafety profile. As an insect virus, it will not 
replicate or recombine with preexisting genetic materials in mammalian cells 
and shows no obvious pathogenicity in targeted cells (Ghosh et al., 2002). 
Secondly, baculovirus is able to accommodate as much as 100 kb or more 
DNA insert and its whole genomic sequence has been determined, providing 
many conveniences for genetic manipulation. The large cloning capacity 
enables the delivery of a large functional gene or several genes within a single 
vector. Thirdly, several commercially available techniques for preparing 
baculovirus have been developed and large amounts of high titer baculovirus 
can be easily prepared in serum-free culture media. This feature paved the 
way for scaling up its manufacture in the pharmaceutical industries and the 
use of serum-free media avoided the potential danger of contamination from 
Chapter One: Introduction 
- 8 - 
the serum of donating animals. Last but not least, compared with other viral 
vectors such as adenovirus, the lack of preexisting immune response against 
baculovirus provides an additional advantage for the use of baculovirus in vivo. 
The recombinant baculoviruses with mammalian expression cassettes were 
able to deliver transgenes into a broad range of cells including primary rat 
chondrocytes (Ho et al., 2004), mouse primary kidney cells (Liang et al., 2004), 
hepatic stellate cells (Gao et al., 2002), human osteosarcoma cell lines (Song 
et al., 2001), human mesenchymal stem cells (Ho et al., 2005) and human 
embryonic stem cells (manuscript in preparation). The in vivo transgene 
expression profile of recombinant baculoviruses could be controlled by the 
route of administration and expression cassettes (Li et al., 2005; Li et al., 2004). 
The use of recombinant baculovirus for human prostate cancer gene therapy 
has been described (Stanbridge et al., 2003). Another recent study has 
explored the use of recombinant baculovirus for RNAi (Nicholson et al., 2005), 
which indicated that a recombinant baculovirus containing the U6 promoter 
was able to knock down targeting mRNA and protein effectively, suggesting 
baculovirus might be an alternative short hairpin RNA (shRNA) delivery system 
without the problems associated with other viral vectors. However, despite a 
good understanding of all these attractive features of baculovirus, most of the 
studies of baculovirus still remain at the stage of reporter gene delivery, and its 
application to glioma gene therapy has not been reported, even in a preclinical 
study. 
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1.4 Control the gene expression at the transcriptional level 
An expression cassette, mainly composed of promoters and other 
regulatory elements, is an important factor that controls the magnitude, 
duration, and specificity of gene expression at the transcriptional level. The 
promoter is the main regulator of gene expression, and can be classified into 
three categories: viral promoter, cellular promoter and hybrid promoter. Other 
regulatory elements include the posttranscriptional regulatory element of 
woodchuck hepatitis virus（Hlavaty et al., 2005）, inverted terminal repeats (ITR) 
of AAV（Chikhlikar et al., 2004; Xin et al., 2003）, and the central polypurine 
tract (Van Maele et al., 2003). The manipulation of the gene expression 
cassette enables us to achieve optimal expression profiles for particular 
therapeutic applications. 
 
1.4.1 Glioma-specific promoter  
  Due to their high transcriptional activity, viral promoters, such as 
cytomegalovirus (CMV) major immediate-early promoter/enhance, have been 
used to achieve robust transgene expression (Kaplitt et al., 1994; McCown et 
al., 1996). However, the application of viral promoters for glioma therapy was 
restricted by their non-specific gene expression properties. For example, after 
injection into the rat striatum of an AAV vector, where the tyrosine hydroxylase 
(TH) gene is under the control of a CMV promoter, the expression of the TH 
gene in neurons was observed (Kaplitt et al., 1994). The untargeted gene 
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expression in neurons, though desirable for the treatment of many neuron 
degenerative diseases such as Parkinson’s disease and Alzheimer's disease, 
will become a serious issue, particularly when toxin genes for glioma therapy 
are used, since the expression of toxin genes in neurons, which have 
important physiological functions, will cause severe adverse effects in the CNS. 
Therefore, the universal viral promoters have gradually been replaced by other 
recently developed glioma or tumor specific promoters in the glioma gene 
therapy. 
  Unlike the viral promoters, the cellular promoters have specificity in driving 
the transgene expression, making it possible to target the transgene 
expression within glioma cells and hence avoid adverse effects caused by the 
over-expression of therapeutic genes in non-targeted normal tissues. 
Candidate promoters for glioma therapy could be tissue-specific promoters 
such as the glial fibrillary acidic protein (GFAP; Vandier et al., 2000; Vandier et 
al.,1998; Ho et al.,2004; Zamorano et al.,2004) and myelin basic protein 
promoters (Shinoura et al., 2000; Miyao et al., 1993; Miyao et al., 1997); 
promoters targeting tumor endothelium (Pore et al., 2003) and tumor-specific 
promoters, such as the nestin promoter (Lamfers et al., 2002), survivin 
promoter (Kleinschmidt-DeMasters et al., 2003), and E2F-1 promoter (Parr et 
al.,1997), which are highly active in many cancer cells as well as in glioma 
cells. The GFAP promoter is a promising candidate for glioma-targeted gene 
expression. It is active in glial cells and gliomas as well, but not, in neurons. A 
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recombinant adenovirus carrying HSV-tk gene under the control of the GFAP 
promoter demonstrated higher level of HSV-tk expression in rat C6 glioma cell 
line than in the non-glial MDA-MB-231 cell line. The subsequent treatment with 
the HSV-tk prodrug ganciclovir (GCV) showed high toxicity in two glial cell lines 
(C6, U251), but low toxicity in the non-glial cell lines tested (Vandier et al., 
2000). This strategy has also been tested in a retroviral vector in which the 
expression of a full-length human growth arrest specific 1(gas1) cDNA is under 
the transcriptional control of a human GFAP promoter (gfa2). It was observed 
that the expression of gas1 caused cell death in vitro and inhibits tumor growth 
in vivo in a transplanted tumor model, by triggering apoptosis (Zamorano et al., 
2004). 
Despite the good cell type specificity of the GFAP promoter, its application 
is curbed by its low transcriptional activity, which, in most cases, is not 
sufficient for glioma therapy. Therefore, further improvements are required to 
enhance the transgenes expression (de Leeuw et al., 2006). An enhanced 
GFAP promoter was created by inserting three additional copies of putative 
GFAP enhancer regions. Compared with original GFAP promoter, this hybrid 
promoter gave 75-fold higher LacZ expression on plasmid transfection into 
U251 cells and approximately 10-fold higher LacZ expression in the context of 
an adenoviral vector (de Leeuw et al., 2006). In addition, when the adenoviral 
vector containing this enhanced promoter was injected into the brain of nude 
mice (de Leeuw et al., 2006), targeted LacZ expression in GFAP positive cells 
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was observed.  
The hybrid promoter composed of a cellular promoter appended with a 
viral enhancer/promoter has been proved to be a successful approach to 
improve transcriptional activity. The CMV enhancer/beta-actin (CAG) promoter 
is a good example. Widely employed in gene therapy, the CAG promoter is a 
robust constitutive promoter composed of the CMV enhancer fused upstream 
to the chicken beta actin promoter (Sawicki et al., 1998; Xu et al., 2001). 
Administered through portal vein injection, an AAV vector with the CAG 
promoter showed 137-fold higher human factor X expression in mouse livers 
than those with the CMV promoter/enhancer (Xu et al., 2001). Besides the 
improvement of transcriptional activity, the retention of cell type specificity is 
also a critical issue. The specificity of this type of hybrid promoter combination 
has been evaluated in previous study. A hybrid promoter-CMV E/PDGF 
promoter-has been constructed by appending the human platelet-derived 
growth factor (PDGF) promoter downstream to a 380-bp fragment of the CMV 
enhancer. When it was employed in the context of plasmid, AAV-2 vectors, or 
baculoviral vectors (Liu et al., 2004; Wang et al., 2005; Li Y et al., 2005), 
improved transgene expression in neuronal cell lines has been achieved 
compared with the vector containing the original PDGF promoter, while a low 
expression level was observed in non-neuronal cell lines. After injection into 
the rat brain, this hybrid promoter demonstrated a neuronal specificity, driving 
luciferase reporter gene expression almost exclusively in neurons.  
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The hybrid promoter might also be a useful approach to improve the 
relatively low transcriptional activity of the GFAP promoter, while retaining the 
cell type specificity, thus creating a suitable promoter for glioma gene therapy. 
 
1.4.2 Expression cassette for siRNA 
Chemically synthesized small interfering RNA (siRNA) duplexes of 21-23nt 
can be delivered into the cytoplasm where they are recruited into the 
RNA-induced silencing complex (RISC) and then trigger the cleavage of target 
mRNA in a sequence-specific manner. Because of the poor intracellular 
stability of siRNA, a more effective way is to use vector-based siRNA 
expression systems that can constitutively express the shRNA (Wadhwa et al., 
2004). shRNA is processed by Dicer, an RNase III-related ribonuclease, into 
siRNA, which then results in silencing of a target gene (Stanislawska et al., 
2005;  Fire et al., 1998). Three types of promoters, including Pol III promoter, 
Pol II promoter, or inducible Pol III promoter can be used in siRNA expression 
(Arendt et al., 2003). The Pol III promoter is in charge of the transcription of 
genes encoding tRNAs, 5S rRNA, and an array of small, stable RNAs (Harvey 
et al., 2003). The rationale for using the Pol III promoter in the siRNA 
expression cassettes is that Pol III transcripts are abundant in human cells 
(Thompson et al., 1995). Pol III promoters can be further classified into three 
categories (type I, type II and type III; Paule et al., 2002), and the two popular 
Pol III promoters, the human U6 small nuclear RNA (snRNA) promoter and the 
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human H1 promoter are both type III promoters. The transcriptional activities of 
the three types of Pol III promoters vary with the composition of promoter 
elements, the promoter position relative to the transcriptional start site, the 
location of a promoter within a given vector, and probably also the type of cells 
tested (Arendt et al., 2003; Ilves et al., 1996; Boden et al., 2003; Koper-Emde 
et al., 2004). Therefore, the choice of a Pol III promoter is a crucial issue in the 
design of shRNA expression cassettes for vector-based RNAi. Alternatively, 
the transcriptional activity of Pol III promoter can be improved through 
modification (Thompson et al., 1995; Paul et al., 2002). For example, the CMV 
enhancer has been employed in one study to improve the activity of U6 
promoter. When the CMV enhancer was placed near the U6 promoter in the 
context of a plasmid, increased shRNA expression and enhanced silencing of 
the target gene was observed (Xia et al., 2003). However, an apparent 
decrease in U6 RNA half-life was accompanied with an increased dose of U6 
gene construct (Noonberg et al., 1996), suggesting the existence of an 
intracellular regulatory mechanism to prevent over-accumulation of U6 RNAs. 
This finding raises concerns regarding the use of U6 promoters for high-level 
expression of shRNA. In the current study, we focused on the H1 promoter, a 
Pol III promoter that is responsible for the transcription of a unique gene 
encoding the RNA component of the nuclear RNase P that cleaves tRNA 
precursors into mature 5’-termini (Myslinski et al., 2001). The H1 promoter has 
four cis-acting elements that are essential for maximal expression, located 
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within 100 bp of the 5’-flanking region. They are characterized by an unusually 
compact structure with the octamer motif and staf binding site near the 
proximal sequence element (PSE) and TATA motif (Myslinski et al., 2001). A 
hybrid promoter was constructed by fusing a 380bp fragment of the CMV 
enhance upstream to the H1 promoter, then in vitro and in vivo experiments 
were carried out to test if this modified H1 promoter was able to enhance the 
gene silencing effects. 
 
1.5 Glioma animal model and non-invasive imaging 
A particular glioma gene therapy protocol cannot be tested in human 
clinical trials until it has been verified on preclinical small laboratory animal 
glioma models. The routinely used tumor models are created by implanting 
glioma cells either into the brains of experimental animals (orthotopic model) or 
into the flank subcutaneously (heterotopic model). A good glioma model should 
have a well-defined in vivo growth profile which resembles the growth of 
human gliomas in the brain. In addition, its response to treatment should be 
similar to that of the human gliomas. Although, till now, there has not been a 
perfect animal glioma model which could exactly mimic the real human 
gliomas, currently available models have provided useful tools for the 
evaluation of glioma gene therapy approaches, among which the C6/Wistar rat 
intracerebral glioma model is one routinely used model for many studies (Barth, 
1998; Zhang et al., 2002). 
Chapter One: Introduction 
- 16 - 
For the success of glioma gene therapy studies, it is also crucial to develop 
techniques to monitor the growth of gliomas in vivo. There are many 
conventional methods including measuring the tumor size with caliper or 
weighing the tumor after dissection. Although these traditional methods are 
straightforward and reliable in some circumstances, their applications were 
restricted by several reasons. There is a large variation in the measurement of 
tumor size with caliper and it is also impossible to directly measure the tumor 
growth of orthotopic glioma xenograft growing in the brain. When the tumor 
weight is used as a parameter, animals have to be sacrificed before each 
measurement. This endpoint measurement usually increases the amount of 
experimental animals needed for statistical analysis. Therefore, many 
researchers are devoted to the development of novel molecular imaging 
approaches, such as magnetic resonance imaging (MRI; Immonen et al.,2004; 
Hamstra et al., 2004), positron emission tomography (PET; Yaghoubi et al., 
2005), and near-infrared fluorescence (NIRF) imaging (Ntziachristos et al., 
2002; Weissleder et al.,1999; Becker et al.,2001; Ntziachristos et al., 2004). 
MRI is a technique that is already used in clinics. The high spatial resolution, 
excellent soft tissues differentiation, and the ability to measure multiple 
physiological and metabolic parameters make it an important tool in the 
diagnosis and treatment of patients with gliomas. To facilitate imaging, a 
contrast agent is usually injected before MRI scanning. Recently developed 
physiologic and metabolic MRI (Cao et al., 2006), magnetic resonance 
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spectroscopy (Nelson, 2003), perfusion-weighted MRI, and proton 
spectroscopic MRI (Law et al., 2005) can provide more sophisticated 
information and will further benefit the treatment of gliomas. PET is another 
imaging approach based on the detection of positron-emitting molecular 
probes labeled with isotopes such as 18F, 11C, 15O, and 124I. For example, PET 
scanning of 18F-fluorodeoxyglucose was used to assess tumor cell viability and 
therapeutic efficacy of HSV-tk suicide gene therapy in C6 glioma model 
(Yaghoubi et al., 2005). NIRF imaging is able to image deeper tissues such as 
intracranial gliomas and get 3-D information (Weissleder et al., 1999) and its 
good performance is attributable to the low background autofluorescence and 
the high tissue-penetrating ability of the near-infrared spectrum (700-900nm) 
used in imaging. Despite the progress of these techniques, none has yet been 
established as a “gold standard” method, especially in pre-clinical animal 
studies.  
In the past few years, the introduction of bioluminescence imaging (BLI) as 
a complementary experimental imaging technique for small animals has 
achieved satisfactory progress. Bioluminescence is the visible light 
(400-620nm) emitted during the oxidation of particular substrate that is 
catalyzed by luciferase. Current available luciferase reporter genes include: 
bacterial Lux genes of terrestrial Photorhabdus luminescens and marine Vibrio 
harveyi bacteria; eukaryotic luciferase Luc gene from firefly species (Photinus); 
eukaryotic luciferase Ruc gene from the sea pansy (Renilla reniformis). The 
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firefly luciferase gene is most widely used to quantify gene expression (Soling 
et al., 2004; Rehemtulla et al., 2002; Ray et al., 2004; Iyer et al., 2004). For 
animal imaging, an instrument composed of a light-tight chamber and a highly 
sensitive CCD camera is used to detect the bioluminescence, mainly the red 
component of emission spectrum, penetrating the tissues and provides 
quantitative information. When the tumor cells are genetically engineered to 
stably express luciferase genes, the progress of the tumor and its response to 
treatment can be non-invasively and quantitatively monitored in vivo (Caceres 
et al., 2003; Jenkins et al., 2003; Uhrbom et al., 2004). When bioluminescent 
PC-3M-Luc-C6 human prostate cancer cells were transplanted 
subcutaneously in a mouse tumor model, a good correlation between 
bioluminescence signal and tumor size measured by caliper was observed 
(Jenkins et al., 2003). The bioluminescence signal also correlated well with the 
total lung weight in an A549-Luc lung colonization model (Jenkins et al., 2003). 
Owing to its high sensitivity, the detection of tumor metastasis has also been 
demonstrated in an HT29 spontaneous metastatic tumor model (Jenkins et al., 
2003). The application of BLI in the intracranial glioma models is particularly 
attractive. By using a luciferase-expression 9L glioma cell, 9L-Luc intracranial 
glioma models have been established, allowing non-invasive monitoring of the 
tumor response to chemotherapy (Rehemtulla et al., 2000) and photodynamic 
therapy (Moriyama et al., 2004). Excellent correlation (r = 0.91) between 
photons detected by BLI and tumor volume measured by MRI was 
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demonstrated (Rehemtulla et al., 2000). The application of BLI and luciferase 
stable expression glioma models have several advantages: generating 
luciferase-stable cell lines is technically simple; the tumor growth before and 
after treatment can be monitored continuously in a real-time manner in 
individual animals thus reducing the subject-to-subject variation and 
minimizing the number of animals needed in the test; and the commercial 
available imaging system for BLI is more affordable than the expensive 
instruments for MRI and PET. Therefore, BLI has been increasingly applied in 
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1.6 Objectives of the study 
The purpose of this study was to investigate the possibility of using a novel 
recombinant baculoviral vector for glioma gene therapy. The expression 
cassette is one crucial element in the vector that determines the magnitude, 
duration, and location of gene expression on transcriptional level. Thus the 
expression cassette could be manipulated to improve the expression profile of 
the gene delivery system. To target the expression of a toxin gene into glioma 
cells, we constructed a recombinant baculovirus with a GFAP promoter-based 
expression cassette. The expression profile of this baculoviral vector carrying 
reporter genes have been characterized in both in vitro and in vivo studies. In 
addition, the therapeutic effects have been evaluated in glioma cell lines and in 
a C6/Wistar glioma model. We also explored in the current study whether a 
recombinant baculovirus harboring a hybrid CMV E/H1promoter could be used 
for RNAi and evaluated the silencing effects in cultured cells and in 
experimental animals. This study on baculovirus will benefit the development 
of gene delivery vectors for glioma gene therapy and provide useful preclinical 
information required for future clinical trials. 
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2.1 Cell lines and experimental animals 
     Human glioma cell lines (BT325, U251, U87, H4, SW1783, and SW1088), 
rat glioma cell lines C6, two non-glioma cell lines (HepG2 and NIH3T3), and 
NT2 human neural precursor cell line were purchased from ATCC (American 
Type Culture Collection, Manassas, VA, USA). To facilitate the quantitative 
measurement of tumor, a stable C6 cell clone with the firefly luciferase gene 
(C6-Luc) was generated. NT2, BT325, U251, U87, H4, HepG2, and NIH3T3 
were cultured in DMEM with fetal bovine serum (10%) and penicillin 
streptomycin (1%). C6 cells were cultured in DMEM supplemented with 0.1 
mM non-essential amino acids, fetal bovine serum (10%), and penicillin 
streptomycin (1%). Complete growth medium supplemented with 0.1mg/ml 
hygromycin were used for luciferase stable cell lines. All above mentioned cell 
lines were cultured at 37ºC in a humidified incubator with 5%CO2. SW1783 
and SW1088 were cultured in Leibovitz's L-15 medium with fetal bovine serum 
(10%) and penicillin streptomycin (1%) at 37ºC in a humidified incubator with 
100% air. Insect Sf9 cell line purchased from Invitrogen was cultured in Sf-900 
II SFM medium with penicillin streptomycin (0.5%) at 27ºC in a non-humidified 
incubator with 100% air. 
 Adult male Wistar rats (weighing 250–300 g) used for in vivo experiments 
were obtained from Centre for Animal Resources in National University of 
Singapore. During the handling and care of animals, we followed the 
guidelines on the Care and Use of Animals for Scientific Purposes issued by 
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National Advisory Committee for Laboratory Animal Research, Singapore. The 
experimental protocols of the current study were approved by the Institutional 
Animal Care and Use Committee (IACUC), National University of Singapore 
and Biological Resource Center, the Agency for Science, Technology and 
Research (A* STAR), Singapore. 
 
2.2 Shuttle plasmids and recombinant baculovirus production 
We constructed nine recombinant baculoviral vectors (Table1) with 
different expression cassettes based on the transfer vector pFastBac1 
(Invitrogen, Carlsbad, CA, USA). Among two of them, a firefly luciferase 
reporter gene (BV-CMV-Luc) or an enhanced green fluorescence protein 
(eGFP) reporter gene (BV-CMV-eGFP) were under the control of the CMV 
enhancer/promoter. GFAP promoter was used in three baculoviral vectors to 
drive the expression of luciferase gene: the first one (BV-GFAP-Luc) has an 
original GFAP promoter; in the second one (BV-CMV E/GFAP-Luc), a hybrid 
GFAP promoter was generated by appending the CMV enhancer (-568 to -187 
relative to the TATA box) to the 5’ end of GFAP promoter; in the third vector       
(BV-CG/ITR-Luc), an expression cassette was constructed by flanking the 
second cassette with AAV ITRs at both ends. In the other two vectors, the 
luciferase gene in BV-CG/ITR-Luc was replaced by a DT-A gene 
(BV-CG/ITR-DTA) or an eGFP gene (BV-CG/ITR-eGFP), respectively.   
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Table 1: Baculoviral vectors used in the current study 
 
Name     Promoter       Transgenes  
 
 
BV-CMV-Luc    CMV       Luciferase                    
 
BV-CMV-eGFP    CMV       eGFP 
 
BV-GFAP-Luc    GFAP       Luciferase 
 
BV-CMV E/GFAP-Luc  CMV E+GFAP     Luciferase 
 
BV-CG/ITR-Luc   CMV E+GFAP, ITR flanking Luciferase 
 
BV-CG/ITR-eGFP     CMV E+GFAP, ITR flanking  eGFP 
 
BV-CG/ITR-DTA   CMV E+GFAP, ITR flanking DTA 
 
BV-H1-siLuc              H1                         Luciferase siRNA 
 
BV-CMV E/H1-siLuc       CMVE+H1                  Luciferase siRNA  
 
To generate BV-CMV E/GFAP-Luc, a CMV enhancer sequence amplified 
from pRC/CMV2 (Invitrogen, Carlsbad, CA, USA) was inserted into pFastBac1 
between the sites of Not I and Xba I, and a GFAP promoter amplified from 
pDRIVE02-GFAP (InvivoGen, San Diego, CA, USA) was subsequently 
inserted downstream of the CMV E between Xba I and Xho I. To construct 
BV-CG/ITR-Luc, an expression cassette from pAAV plasmid (Wang et al., 
2005), containing a multiple cloning site (MCS), a reporter gene encoding 
luciferase, a SV40 polyA signal, and two ITR sequences at both ends, was 
amplified and inserted into pFastBac1 between Avr II and Sal I. The CMV 
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E/GFAP promoter was then inserted into the sites of Kpn I and Hind III. The 
BV-CG/ITR-eGFP and BV-CG/ITR-DTA were constructed by inserting an 
eGFP reporter gene from peGFP-C1 vector (Clontech, Mountain View, CA, 
USA), or a DT-A gene amplified from pCAG/DT-A-2 (kindly provided by Dr. 
Masahiro Sato, Tokai University, Japan), respectively, into the downstream of 
the GFAP promoter between the sites of Hind III and Xba I to replace the 
luciferase gene. BV-CMV-Luc and BV-CMV-eGFP were constructed by 
inserting the CMV promoter amplified from pRC/CMV2 into pFastBac1 
between the Not I and Xba I and inserting between the sites of Xho I and Hind 
III with a luciferase gene from pGL3-basic vector (Promega, Madison, WI, USA) 
or eGFP gene from peGFP-C1 vector (Clontech, Mountain View, CA, USA), 
respectively.  
For the two vectors carrying siRNA genes, H1 promoter (BV-H1-siLuc) or 
hybrid CMVE/H1 promoter was used in the expression cassettes of siRNA 
targeting against luciferase. pRNAT-H1.1/Neo containing the human H1 
promoter was purchased from GenScript (Piscataway, NJ, USA). To construct 
the hybrid CMV E/H1 promoter, a CMV enhancer element (-568 to –87 relative 
to the TATA box of the CMV immediate-early promoter) was amplified from 
pRC/CMV2 (Invitrogen, Carlsbad, CA, USA) and subcloned into 
pRNAT-H1.1/Neo at the 5’ region of the Pol III promoter between the sties of 
Mlu I and Bgl II. Oligonucleotides 
(5’-GCTTACGCTGAGTACTTCGATTCAAGAGATCGAAGTACTCAGCGTAAG
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CTTTTT-3’) targeting against the firefly (Photinus pyralis) luciferase coding 
region with cohesive BamH I and Hind III sites were chemically synthesized, 
annealed and cloned into pRNAT-H1.1/Neo or pRNAT-H1.1/Neo with the CMV 
enhancer. The two plasmid vectors were named pH1-siLuc and pCMV 
E+H1-siLuc, respectively. To construct recombinant baculoviral vectors with  
shRNA expression cassette, the firefly luciferase siRNA hairpin-loop sequence 
under the H1 promoter or the hybrid CMV enhnacer/H1 promoter was 
amplified from pH1-siLuc and pCMV E+H1-siLuc and subcloned into the 
transfer vector pFastBac1. The two recombinant baculoviral vectors were 
named BV-H1-siLuc and BV-CMV E/H1-siLuc, respectively. 
 Recombinant baculoviruses were produced and propagated in Sf9 
insect cells according to the manual of the Bac-to-Bac baculovirus expression 
system (Invitrogen, Carlsbad, CA, USA). To concentrate recombinant 
baculoviruses, the clear supernatant was filtered with 0.45μm membrane, 
centrifuged at 28,000×g for 1 hour at 4ºC and the pellet was suspended with 
appropriate volume of 1X PBS by vortexing 30 minutes. The titers 
(plaque-forming units, PFU) of the recombinant baculovirus vectors were 
determined by plaque assay on Sf9 cells. The prepared baculovirus stocks 
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2.3 Virus transduction 
For in vitro transduction, cells were seeded in 96-well plates at a density of 
1,000 cells per well or 48-well plates at a density of 20,000 cells per well for 
luciferase activity assay, in 12-well plates at  a density of 100,000 cells per 
well for flow cytometric analysis, in 96-well plates at a density of 10,000 cells 
per well for MTT assay, in 6-well plate at a density of 100,000 cells per well for 
RT-PCR analysis and in 24-well plates with a density of 30,000 cells per well 
for gene silencing experiments. Cells were incubated with appropriate 
amounts of baculoviral vectors in DMEM at 37°C for 1 hour. After the 
incubation, DMEM containing the viruses was replaced by complete growth 
medium and the infected cells were cultured in normal condition. 
To characterize the gene expression profiles in vivo, C6 or C6-Luc cells (1 
x 105 in 5 μl) were first implanted into the striatum on one side of the rat brain. 
Three days later, 5 x 107 viral particles of BV-CG/ITR-eGFP or 5 x 106 of 
BV-CG/ITR-Luc in 3 μl were injected into the same region, as well as the 
contralateral striatum in some animals.  
To test in vivo gene silencing effects, BV-H1-siLuc, BV-CMV E+H1-siLuc or 
the control vector BV-CMV-eGFP, 9 x 107 virus particles each, were injected 
together with BV-CMV-Luc (3 x 106 PFU per brain). Rats were euthanized 2 
days after viral injection and the brain tissues were collected for gene 
expression analysis.  
To test the inhibition of tumor growth in vivo, 100,000 C6-Luc cells were 
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implanted into the striatum on both sides of the rat brain. Three days later, 1x 
107 viral particles in 3μl were injected into the striatum at the same site. 
BV-CG/ITR-DTA was injected into the left side and BV-CG/ITR-eGFP, serving 
as a viral vector control, into the right side.  
A standard operation protocol of the stereotaxic injection was followed. 
Briefly, rats were anesthetized with intraperitoneal injection of sodium 
phenobarbital (60mg/kg) and positioned in a stereotaxic instrument (KOPF, 
Model 900, USA) with the nose bar set at 0. Then a skin incision of about 1 cm 
in length was made in the appropriate position and the cranial bone was 
exposed. A small hole was made in the skull by a dental drill according to the 
stereotaxic anatomy atlas of rat brain. The cells or viruses were injected into 
the striatum (AP+1.0 mm, ML +2.5 mm, and DV -5.0 mm from bregma and 
dura) through the hole using a 10 μl Hamilton syringe connected with a 
30-gauge needle at a speed of 0.5 μl/min. At the end of each injection, the 
needle was allowed to remain in place for additional 5 minutes before being 
slowly retracted to prevent the backflow. 
 
2.4 Luciferase activity assay 
To measure the luciferase expression in cultured cells, the growth medium 
were carefully remove from the cells, and the cells were rinsed with 1X PBS 
with care to avoid cell dislodging. Then cells were permeabilized by adding 
appropriate volume of 1X reporter cell lysis buffer (Promega, WI, USA), 
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followed by two freeze/thaw cycles to further lyse the cells, and thus release 
the luciferase. To measure the luciferase expression in brain tissues, rats were 
perfused with 100ml 1X PBS after deep anesthesia. Brain tissue samples were 
collected, homogenized by sonicator in 1X PBS (100 μl PBS per 50 mg tissue) 
for 10 sec on ice, and centrifuged at 13,000 rpm for 10 minutes at 4°C. The cell 
lysates or the supernatants of homogenized tissues were used for luciferase 
activity assays with a luciferase assay kit (Luciferase Assay System, Promega, 
WI, USA) in a single-tube luminometer (Berthold Lumat LB 9507, Bad Wildbad, 
Germany). Ten μl of sample was mixed with 50μl of substrate from the 
luciferase assay kit in a 10ml plastic tube. For in vitro study, the luciferase 
activity was represented by relative light units (RLU) per 1000 cells. For the 
luciferase expression in brain, the results were represented by RLU per region. 
Luciferase activity in the protein synthesis inhibition experiment on C6-Luc 
cell line and in the in vitro gene silencing experiment were monitored by BLI 
with the IVIS® Imaging System (Xenogen, Alameda, California, USA) 
comprised of a highly sensitive, cooled CCD camera mounted in a light-tight 
specimen box. Two to five minutes prior to cell imaging, luciferin-EF (150 μg/ml 
in 1X PBS; Promega, Madison, WI, USA) was added to each well. 
Bioluminescence emitted from the cells was acquired for 30s and quantified as 
photons/second using the Living Image software (Xenogen, Alameda, 
California, USA). In some experiments, bioluminescence was digitized and 
electronically displayed as pseudocolor. 
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2.5 Detection of eGFP expression 
      The expressions of eGFP in glioma cell lines were observed directly 
with an inverted fluorescent microscope (Olympus IX71, USA). The 
transduction efficiency was quantitatively measured by counting the 
percentage of eGFP positive cells with flow cytometric analysis. For flow 
cytometric analysis of eGFP expression, at certain time post transduction, 
glioma cells were washed with 1X PBS, trypsinized, suspended in 1X PBS and 
directly introduced to a FACSCalibur Flow Cytometer (Becton Dickinson, NJ, 
USA) equipped with a 488 nm argon ion laser. The FL-1 emission channel was 
used to monitor the eGFP expression and results from 10,000 fluorescent 
events were obtained for analysis. Cells without virus transduction were served 
as negative controls. Three sets of independent transduction experiments 
were carried out for each assay. 
 
2.6 RT-PCR  
For detection of DTA expression, total RNA was extracted from U251 cells 
transduced with BV-CG/ITR-DTA or BV-CG/ITR-eGFP using RNeasy® Mini 
KIT (Qiagen, USA ) after on-column DNase digestion (RNase-Free DNase Set, 
Qiagen, USA). RNA concentration was determined by spectrophotometer 
(NanoDrop® ND 1000, USA). The DTA mRNA expression was determined 
with SuperScript One-Step RT-PCR with Platinum® Taq kit (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer’s protocol. Briefly, 1μg of 
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the total RNA sample was used as the starting material for end-point RT-PCR 
detection and analysis. Gene specific primers for the DTA gene were used,  
Forward primer: 5’-AAATACGACGCTGCGGGAT-3’, 
Reverse primer 5’-GAAGGGAAGGCTGAGCACTA-3’.  
RT-PCR reaction was carried out in an Eppendorf® thermal cycle using 
the following program: 50°C for 30 minutes and 94°C for 2 minutes, followed 
by 38 cycles of 94°C for 15 sec, 58°C for 30 sec, and 72°C for 1 minutes, and 
final extension at 72°C for 10 minutes.  
For the detection of luciferase mRNA, 1 μg of total RNA from each sample 
was used for the synthesis of first strand cDNA with SuperScript III First Strand 
Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA). Oligo-dT was 
used as primer. The cDNA was synthesized according to manufacturer’s 
protocol. 1 μl of cDNA from each sample was used for PCR amplification. Each 
reaction also contained 10 μl of TaqPCR Master Mix (Qiagen, USA), 1 μl each 
of forward and reverse primers, and 7 μl of distilled water to make up a 20 μl 
reaction volume. As a control to demonstrate equal amount of RNA used, each 
sample was also amplified for the endogenous house-keeping gene, GADPH, 
under the same conditions. For the PCR-detection of luciferase mRNA, the 
primers used were  
Forward primer 5’-CGAGGTGGACATCACTTACGCTG-3’,  
Reverse primer 5’-CGAGAATCTCACGCAGGCAGTTC-3’.  
The primers used for PCR amplification of GADPH were  
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Forward primer 5’-GAAGATGGTGATGGGATTTC-3’, 
Reverse primer 5’- GAAGGTGAACGTCGGAGT-3’. 
Aliquots of RT-PCR products were analyzed by gel electrophoresis on a 
1% agarose gel containing ethidium bromide at a voltage of 80mV for 
60minutes, and visualized by UV. 
 
2.7 Fluorescence immunohistochemistry 
  Florescence immunohistochemistry was used to analyze cell type 
specificity of transgene expression. After deep anesthesia, rats were perfused 
with 100ml 1X PBS and 100ml 4% paraformaldehyde in 1X PBS. The brain 
was taken out with care and incubated in the same fixative (4% 
paraformaldehyde) for 2–4 hours before being transferred into 20% sucrose in 
1X PBS for incubation overnight at 4°C. Coronal sections of each brain were 
cut with cryostat (Leica CM3050S, USA). One piece of brain sample was put 
on the cryostat stage, covered with OCT medium, and snap froze in liquid 
nitrogen for 30 seconds. Then it was transferred to the cryostat chamber and 
sectioned at thickness of 30µm. Sections of the regions of interest were 
collected with care and transferred to a 6-well plate containing 1X PBS. A 
free-floating immunostaining protocol was followed. Briefly, sections were 
washed with washing solution (1X PBS containing 0.2% Triton X-100) for three 
times 10minutes each, then blocked in blocking solution (1X PBS containing 
0.2% Triton X-100 and 5% normal goat serum) for 1 hour at room temperature. 
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Primary antibody diluted in washing solution was added and incubated 
overnight at 4 °C with gentle shaking. On the following day, sections were 
washed with washing solution three times 10minutes each, secondary 
antibody with a proper dilution was added and incubated at RT for 1 hour 
preventing from light. After this incubation, sections were washed with 1X PBS 
for five times 10minutes each. The sections were then carefully transfer onto a 
gelatin-coated slide, cover with a drop of fluorescent mounting solution (DAKO, 
USA), add cover slip, and store the slide at 4 °C overnight to allow mounting 
medium to set. Sections were observed with a confocal laser scanning 
microscope (Leica, TCS SP2 RS, USA). A anti-luciferase polyclonal antibody 
(Sigma–Aldrich, USA, dilution 1:150) or a anti-GFAP polyclonal antibody 
(Promega, USA, dilution 1:150) was used as the primary antibody to show 
implanted C6 glioma cells, as well as nearby astrocyte, while the expression of 
eGFP could be observed without fluorescence staining. Anti-rabbit IgG TRITC 
conjugate (Sigma–Aldrich, USA; dilution 1:500) was used as the secondary 
antibody. 
 
2.8 Cell viability assay 
Cells seeded in 96-well plates were transduced with BV-CG/ITR-DTA or 
BV-CG/ITR-eGFP. Six days after virus transduction, 20 μl of 5 mg/ml MTT (3-(4, 
5-dimethyl-thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) in 1X PBS was 
added to each well to reach a final concentration of 0.5mg/ml. After 4 hours 
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incubation at 37°C, the medium was removed and 200 μl of DMSO was added 
into each well to dissolve the formazan crystals. The absorbance was 
measured in a microplate reader at a wavelength of 550 nm (BioRad, Module 
550, USA). The relative cell growth (%) comparing with control cells without 
virus infection was calculated as Atest/AcontrolX100% 
 
2.9 Rat C6 glioma xenograft model and tumor growth monitoring  
To establish a rat C6 tumor xenograft model, C6-Luc cells were trypsinized, 
harvested by centrifugation, and suspended in 1X PBS. Then the cells 
suspended in 5μl 1X PBS were implanted into the brain following the 
stereotaxic injection protocol described in section 2.3. To measure the tumor 
size, brain samples were taken at certain time points post implantation and 
coronal sections with thickness of 0.3mm were cut out by cryostat (Leica 
CM3050S, USA) as described above in section 2.7. β-gal staining (β-gal 
staining kit, Invitrogen, Carlsbad, CA, USA) was used to visualize the C6-Luc 
cells which also have the LacZ gene expression. The staining protocol 
provided by the manufacture was followed with some optimization. The 
incubation time of staining solution was increased to 4 hours. After staining, 
sections were observed under microscope and the area of tumor was 
measured. The total size of the tumor was calculated by following formulation: 
Tumor size (mm3) =0.3 X (A1 + A2 + --- + An); in where An is the tumor area in 
each section  
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Tumor growth was also monitored by either luciferase activity assay of 
brain tissues or BLI of C6-Luc cells in living animals. To monitor glioma growth 
with luciferase activity assay, brain samples were collected and the luciferase 
activity was measured as described in section 2.4. 
BLI was performed with the IVIS Imaging System (Xenogen, Alameda, 
California, USA). Briefly, ten minutes before in vivo imaging, anesthetized 
animals were intraperitoneally injected with D-luciferin (Promega, WI, USA) at 
a concentration of 40 mg/kg in 1X PBS. The animals were then placed onto a 
warmed stage inside the camera box. The detected light emitted from C6-Luc 
cells was digitized and electronically displayed as a pseudocolor overlay onto 
a gray scale animal image. Images and measurements of luminescent signals 
were acquired and analyzed using the Living Image software (Xenogen, 
Alameda, California, USA). Animals were euthanized 14 days after virus 
injection. 
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3.1 Establishment of C6 glioma xenograft model  
For the evaluation of gene therapy approaches, it is important to have a 
reliable tumor model that can mimic the growth profiles of gliomas in vivo. 
C6/Wistar rat xenograft model has been widely used in the studies of glioma 
therapy (Barth et al., 1998; Zhang et al., 2002). In addition, the ease of 
monitoring tumor growth and the tumor’s response to treatments is another 
criterion for a good tumor model. In the current study, the C6 glioma cells have 
been genetically engineered to have stable luciferase expression in order to 
facilitate the monitoring of tumor by BLI or luciferase activity assay. As 
indicated in Fig. 1, with increased amount of C6 cells implanted into the brain 
(from 10,000 to 1,000,000), the tumor size increased correspondingly (from 
4.2 to 39.9 mm3) and a similar increase profile was observed in the results 
based on the luciferase activity assay (Fig. 2A). A good correlation between 
the tumor size measurement and luciferase activity assay (Fig. 2B) was 
demonstrated (R2 = 0.9998), which indicated that the luciferase activity assay 
was a reliable method to monitor the glioma growth in vivo. Therefore, the 
growth of gliomas over time could also be monitored by either luciferase 
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Fig. 1 Monitoring the C6 glioma xenograft model by calculating the tumor size. 
Various number of C6-Luc cells (also with lacZ gene expression) were implanted into the 
rat brain with stereotaxic injection. One week after implantation, brain sections were 
treated with lacZ staining. (A) C6 glioma formed in the rat brain was visualized by lacZ 
staining. (B) Increase of tumor size with increased number of cells implanted. Tumor size 
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Fig. 2 Monitoring the C6 glioma xenograft model by luciferase activity assay.     
(A) Various number of C6-Luc cells were implanted into the rat brain with stereotaxic 
injection. One week after implantation, brain samples were taken for luciferase activity 
assay. Luciferase activity increased with the increased number of cells implanted. 
Columns, mean (n = 3); bars, SD. (B) There was a good correlation between the tumor 
size and luciferase activity. (C) 100,000 C6-Luc cells were implanted into the rat brain with 
stereotaxic injection. One, two, and three weeks after implantation, brain samples were 
taken out for luciferase activity assay. Points, mean (n=3); bars, SD. 
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3.2 DTA expressing baculovirus-mediated inhibition of glioma cell 
growth 
3.2.1 Effective transduction of glioma cells by baculoviral vectors 
Although recombinant baculovirus has been shown to be able to transduce 
various types of mammalian cells (Kost et al., 2002), its ability to deliver 
transgenes into glioma cells has not yet been well characterized. Therefore, 
two baculoviral vectors with different reporter genes, namely BV-CMV-Luc 
(luciferase gene) and BV-CMV-eGFP (eGFP gene), under the control of the 
CMV promoter were first used to test the baculovirus-mediated gene delivery 
in seven glioma cell lines, including C6, H4, SW1088, SW1783, U87, U251 
and BT325. The ubiquitous transcriptional activity of the strong CMV promoter 
enabled the comparison of the gene expression levels between these glioma 
cell lines with different grades of malignancy. As indicated in Fig. 3, 
BV-CMV-Luc was able to achieve comparable levels of luciferase expression 
in all the tested gliomas cell lines in a dose-dependent pattern, though with a 
slightly higher level in U87 and lower level in SW 1783 at a multiplicity of 
infection (MOI) of 100 or 200. For BV-CMV-eGFP, the eGFP expression in 
glioma cells was observed as early as 4 to 6 hours post transduction. The flow 
cytometric analysis of these cells 24 hours post transduction showed a 
dose-dependent increase of the percentage of eGFP positive cells, ranging 
from 30% to 70% at a MOI of 100 (Fig. 4). Further increase of the MOI to 200 
achieved only 10% improvement, indicating a plateau of the transduction 
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Fig. 3 Transduction of glioma cells with baculovirus with luciferase reporter gene. 
Cells were transduced with BV-CMV-Luc with increased MOI from 1 to 100. Luciferase 
activity assay was carried out one day after infection. The results are expressed in relative 
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Fig. 4 Transduction of glioma cells with baculovirus with eGFP reporter gene. Cells 
were transduced with BV-CMV-eGFP with increased MOI from 10 to 200 and analyzed 
with flow cytometry one day later. The results are reported as the percentage of 

































200 50 0 100 150
                                        Chapter Three: Results 
- 43 - 
 
3.2.2 Modified GFAP promoters improve transgene expression to glioma 
cells  
  The use of cell type-specific promoter is an important strategy to drive the 
expression of therapeutic genes within targeted cells, while reducing adverse 
effects caused by over-expression of therapeutic genes in non-target cells. In 
order to restrict the gene expression in glioma cells, we constructed a 
baculoviral vector, BV-GFAP-Luc, in which a luciferase expression was under 
the control of a GFAP promoter (Fig. 5A). However, only a low level of 
luciferase expression was achieved in the tested glioma cells, being 10 to 
several hundred-fold lower than those from the baculoviral vector containing 
the CMV promoter (BV-CMV-Luc; Fig. 5B). To enhance the transcriptional 
activity of the GFAP promoter, two additional transcriptional regulatory 
elements were incorporated into the expression cassette of the baculoviral 
vector (Fig. 5A). In one of the modification (BV-CMV E/GFAP-Luc), we inserted 
the CMV enhancer from cytomegalovirus upstream to the GFAP promoter; in 
another one (BV-CG/ITR-Luc), we flanked the expression cassette (hybrid 
CMV E/GFAP promoter and luciferase transgene) with the ITR sequences 
from adeno-associated virus. As indicated in luciferase activity assay (Fig. 5B), 
the CMV enhancer greatly increased the transcriptional activity of the GFAP 
promoter in all tested glioma cell lines, leading to high levels of luciferase 
expression comparable to those achieved with baculovirus containing the 
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strong CMV promoter. The AAV ITR flanking further increased the luciferase 
expression by at least 10 folds compared with BV-CMV E/GFAP-Luc. In 5 out 
of 7 tested glioma cell lines, even higher levels of luciferase expression were 
achieved from BV-CG/ITR-Luc compared with BV-CMV-Luc (Fig. 5B). It was 
also observed that although BV-CMV-Luc provided similar levels of luciferase 
expression in two non-glioma cell lines, namely HepG2 and NIH3T3, 
BV-GFAP-Luc, BV-CMV E/GFAP-Luc and BV-CG/ITR-Luc, in contrast, showed 
significant lower levels of luciferase expression in HepG2 and NIH3T3 cells, 
when compared to those in glioma cell lines (Fig. 5B). Since similar levels of 
transgene expression in the two non-glioma cell lines and those glioma cell 
lines were achieved by BV-CMV-Luc, the difference in cellular uptake and 
intracellular transport of baculovirus per se should not be the reason for the 
low levels of transgene expression in HepG2 and NIH3T3 cells. These results 
indicated that our modification of the GFAP promoter was able to enhance the 
transcriptional activity, while retaining good cell type specificity.  
Although the luciferase activity assay is a sensitive quantitative method for 
comparison of gene expression levels, especially in the study to compare the 
transcriptional activity of different gene expression cassettes, the eGFP 
reporter gene can provide direct information regarding the transduction 
efficiency based on the percentage of eGFP positive cells. For this purpose, a 
baculovirus with hybrid CMV E/GFAP promoter flanked by AAV ITR sequences 
to drive the expression of the eGFP gene (BV-CG/ITR-eGFP) was constructed 
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by replacing the luciferase gene with the gene encoding eGFP (Fig. 6A). When 
this baculovirus was tested, a high level of eGFP expression in glioma cell 
lines was observed with the inverted florescence microscope (Fig. 6C). Flow 
cytometric analysis indicated a significant improvement in transduction 
efficiency over the those achieved from baculovirus with CMV promoter 
(BV-CMV-eGFP) in all the tested glioma cell lines, with percentage of eGFP 
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Fig. 5 Modified GFAP promoters improved baculovirus-mediated luciferase 
expression in glioma cells. (A) Schematic diagram of the expression cassettes used in 
the study. BV, baculovirus; CMV, the promoter/enhancer of cytomegalovirus 
immediate-early gene; GFAP, the promoter of the glial fibrillary acidic protein; CMV E, the 
enhancer of cytomegalovirus immediate-early gene; ITR, AAV inverted terminal repeats; 
Luc, luciferase gene; pA, SV40 polyA signal. (B) Cells were infected with the baculoviral 
vectors with a luciferase reporter gene under the control of different expression cassettes 
at an MOI of 25. Luciferase activity assay was performed one day after transduction. 
Results are reported as the percentage of RLU produced by the vector with the CMV 
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Fig. 6 Modified GFAP promoters improved baculovirus-mediated eGFP expression 
in glioma cells. (A) Schematic diagram of the expression cassettes used in this study. 
BV, baculovirus; CMV, the promoter/enhancer of cytomegalovirus immediate-early gene; 
GFAP, the promoter of the glial fibrillary acidic protein; CMV E, the enhancer of 
cytomegalovirus immediate-early gene; ITR, AAV inverted terminal repeats; eGFP, 
enhance green fluorescence gene; pA, SV40 polyA signal. (B) Cells were infected with 
the baculoviral vectors with two different expression cassettes at an MOI of 100 and 
analyzed with flow cytometry one day later. The results are reported as the percentage of 
eGFP-positive cells. The results from the experiment with BV-CMV-eGFP in Fig. 4 are 
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Fig. 6 Modified GFAP promoters improved baculovirus-mediated eGFP expression 
in glioma cells (C) Cells were infected with BV-CG/ITR-eGFP at an MOI of 100 and 
pictures were taken with digital camera attached to Olympus IX71 inverted fluorescence 
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3.2.3 Inhibition of protein synthesis and glioma cell growth in vitro  
In order to explore the feasibility of using baculovirus as a vector for glioma 
gene therapy, a recombinant baculovirus (BV-CG/ITR-DTA) was constructed 
by replacing the luciferase reporter genes in BV-CG/ITR-Luc with the gene 
encoding diphtheria toxin A-chain. In this baculoviral vector, the DTA gene 
expression was under the control of an expression cassette composed of 
hybrid CMV E/GFAP promoter and flanked by AAV ITRs. Owing to the tight 
transcriptional control of this GFAP promoter based expression cassette in the 
insect cells, high titer viral preparation were successfully produced in Sf9 
insect cells despite the high toxicity of DTA. We first confirmed this baculoviral 
vector (BV-CG/ITR-DTA) mediated DTA expression in U251 glioma cells by 
RT-PCR using DTA gene specific primers (Fig. 7). Then the inhibition of protein 
synthesis in glioma cell lines by BV-CG/ITR-DTA was evaluated according to a 
method first reported by Maxwell (Maxwell et al.,1986), which is an indirect 
method based on the effects of DTA on co-expressed luciferase protein. Six 
glioma cell lines, namely H4, SW1088, SW1783, U87, U251 and BT325, were 
co-transduced with BV-CMV-Luc and BV-CG/ITR-DTA or BV-CMV-Luc and 
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Fig. 7 RT-PCR analysis of DTA expression. U251 cells were infected BV-CG/ITR-DTA 
at an MOI of 100. 48 hours after transduction, total RNA was extracted for RT-PCR 
analysis with DTA gene specific primers. Down arrow: A clear PCR band with a 




As demonstrated in Fig. 8, a significant reduction of the luciferase activity 
was observed in all the tested glioma cell lines transduced with the 
BV-CG/ITR-DTA, even at a low MOI of 10, varying from around 50% inhibition 
in BT325 to almost 90% inhibition in SW1088 cells. Although a slightly 
reduction of the luciferase activity after transduction with control virus 
(BV-CG/ITR-eGFP) was observed in some tested glioma cell lines, the more 
dramatic effects were obvious when the viruses expressing DTA 
(BV-CG/ITR-DTA) were used. 
For the evaluation of DTA inhibition effects over time, BLI with the IVIS® 
Imaging System was used to continuously monitor the temporal change of 
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luciferase activity over 6 days in C6-Luc cells, which were genetically modified 
to stably express the luciferase gene. As demonstrated in Fig. 9, 
BV-CG/ITR-DTA transduction resulted in an obvious reduction of luciferase 
activity in C6-Luc cells, from 59% of the control on day 2 to 32% on day 6 at an 
MOI of 50, and from 38% of the control on day 2 to 14% by day 6 at an MOI of 
100. Inhibition of protein synthesis might eventually lead to cell death, which, in 
turn, would be another reason for the reduction of luciferase activity on day 6. 
At the MOI of 10, from 20% to 30 % inhibition was observed on day 2 and 3 but 
not at later time points, this is probably due to rapid proliferation of 
untransduced C6-Luc cells (Fig. 9). Cell viability assay was carried out to 
evaluate the effects of BV-CG/ITR-DTA on cell growth directly. The inhibition of 
cell growth was tested in two glioma cell lines (C6-Luc and U87), as well as in 
two non-glioma cell lines (HepG2 and NIH3T3). These cells were transduced 
with BV-CG/ITR-DTA or BV-CG/ITR-eGFP at an MOI of 100, and the MTT 
assay was performed 6 days post transduction. As indicated in the cell viability 
results (Fig.10), transduction of BV-CG/ITR-DTA led to 90% of growth inhibition 
in C6-Luc cells and 40% in U87 glioma cells, but had no obvious effects in 
HepG2 and NIH3T3 cells. However, no significant inhibition of cell growth was 
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Fig. 8 BV-CG/ITR-DTA mediated inhibition of protein synthesis in cultured 
glioma cell lines. Protein synthesis inhibition, as demonstrated by the reduction of 
luciferase activity, was measured 48 hours after transduction with increased MOI from 10 
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Fig. 9 BV-CG/ITR-DTA mediated inhibition of protein synthesis in C6-Luc cell 
line. After transduction of BV-CG/ITR-DTA in C6-Luc cells, time-dependent effects over 6 
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Fig. 10 BV-CG/ITR-DTA mediated selective inhibition of glioma cell growth in vitro. 
Cells were transduced with BV-CG/ITR-DTA or BV-CG/ITR-eGFP (as control) at an MOI 
of 100. Six days after baculovirus transduction, cell viability was determined by MTT 
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3.2.4 Expression of reporter genes in glioma xenograft    
In order to further investigate the use of recombinant baculovirus for 
glioma therapy in vivo, the baculovirus-mediated expression of two reporter 
genes encoding eGFP or luciferase were evaluated in the C6 glioma xenograft 
model. In the first study, C6-Luc cells were implanted into the rat striatum and 3 
days later BV-CG/ITR-eGFP was injected into the glioma at the same position. 
Two days after baculovirus injection, the brain sample was collected and an 
immunohistochemistry study was carried out. The eGFP expression was 
observed in luciferase-positive C6 cells (Fig. 11). In the sections stained with 
antibodies against GFAP, the reactive gliosis was observed, marking the 
boundary of solid glioma by a rim of reactive astrocytes with strong GFAP 
signal. High level eGFP expression was also observed in many of these 
reactive astrocytes (Fig. 11, the right panel). However, no detectable eGFP 
expression was observed in the normal tissues outside the gliosis rim. 
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Fig. 11 In vivo eGFP reporter gene expression in gliomas mediated by baculovirus 
carrying the hybrid CMV E/GFAP promoter and ITRs. BV-CG/ITR-eGFP was injected 
into the rat striatum that was inoculated with C6-Luc glioma cells 3 days before. 
Immunostaining was carried out to show C6 cells and nearby astrocytes, while eGFP 
expression could be visually detected under a fluorescent microscope without 
immunostaining. The left panel, immunostaining with antibody against luciferase show 
glioma tissues. The right panel, immunostaining with antibody against GFAP show 
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To compare the in vivo transgene expression levels in glioma cells and 
normal astrocytes, a recombinant baculovirus with luciferase gene 
(BV-CG/ITR-Luc) was used. C6 glioma cells without modification were 
implanted into one side of the rat striatum three days before virus injection. 
Then same amount of BV-CG/ITR-Luc were injected into the C6 
cells-inoculated brain region and the contralateral side of the rat brain without 
C6 inoculation, respectively. Two days post virus injection, the brain tissues 
were collected and the luciferase activity was measured. As shown in Fig. 12, 
luciferase expression level in C6-inoculated brain region was 10 folds higher 
than that in normal brain, which might be due to the higher transcriptional 





Fig. 12 In vivo luciferase gene expression in gliomas mediated by baculovirus 
carrying the hybrid CMV E/GFAP promoter and ITRs. BV-CG/ITR-Luc was injected 
into the rat striatum inoculated with C6 glioma cells (without the luciferase gene) 3 days 
before, and the contralateral normal striatum. Luciferase expression was measured 2 
days after the virus injection by luciferase activity assay. The results are expressed in 
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3.2.5 Inhibition of glioma xenograft growth 
After showed the BV-CG/ITR-DTA mediated effective inhibition of glioma 
cell growth in vitro and the efficient transfer of reporter genes into the glioma 
cells in vivo with recombinant baculovirus with same expression cassette, we 
further test the anti-glioma effects of BV-CG/ITR-DTA in vivo in a C6 glioma 
xenograft model. C6-Luc cells were implanted into the striatum at both 
hemispheres of the brain. Three days later, we injected BV-CG/ITR-DTA into 
the left striatum and BV-CG/ITR-eGFP as the control into the right striatum at 
the same site as those for glioma cell implantation. BLI with IVIS imaging 
system was used to non-invasively monitor the glioma tumor growth in living 
animals on 0, 3, 7 and 14 days after virus injection. The bioluminescence 
signals from the implanted C6-Luc cells on the control side were detectable 
from day 3 and the intensity of bioluminescence signals increased 
continuously during the 14-day experiment. In contrast, on the 
BV-CG/ITR-DTA injected side of the same rat, no detectable bioluminescence 
signals were observed (Fig. 14A). Quantitative results from these rats are 
summarized in Fig. 14B, indicating a significant inhibition of C6 glioma cell 
growth in vivo by just one injection of BV-CG/ITR-DTA. We also performed 
luciferase activity assay to monitor the glioma tumor growth in the brain. Brain 
tissue samples from both sides of C6-Luc implanted rats were collected at day 
0 (3 days post C6 cell implantation) and day 14 post the baculovirus injection. 
Before the virus injection (day 0), there is no obvious difference in luciferase 
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activities from two sides of the brain. But after two weeks of viral injection, a 
30-fold higher luciferase activity was observed on the BV-CG/ITR-eGFP 
injected side, when compared with that in BV-CG/ITR-DTA-injected side (Fig.  
13), which indicated that the DTA expression mediated by BV-CG/ITR-DTA 







Fig.13 Monitoring the C6 glioma xenograft growth in the rat brain by luciferase 
activity assay. Rats were inoculated with C6-Luc cells to each side of the brain, followed 
by injection of BV-CG/ITR-DTA on the left side and BV-CG/ITR-eGFP on the right side 3 
days later (designated as day 0). Measurement of tumor growth by luciferase activity 
assays of brain tissues collected at day 0 (n=3) and day 14 (n=5). The results are 
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Fig. 14 Monitoring the C6 glioma xenograft growth in the rat brain by BLI. Rats were 
inoculated with C6-Luc cells to each side of the brain, followed by injection of 
BV-CG/ITR-DTA on the left side and BV-CG/ITR-eGFP on the right side 3 days later 
(designated as day 0). (A) In vivo bioluminescent images of the brains with inoculated 
C6-Luc cells 3, 7 and 14 days after virus injection in a living animal. The luminescent light 
emitted from the side injected with the control viruses was easily detected and increased 
over time. No light could be detected on the BV-CG/ITR-DTA injected side. (B) 
Quantification of in vivo bioluminescence. Point, mean photon counts over time; bars, SD. 
Photon counts at day 0 were not much different form background bioluminescence. n = 6 
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3.3 siRNA expressing baculovirus-mediated gene silencing 
3.3.1 Knockdown of luciferase gene expression in cultured cells 
To explore the feasibility of using baculovirus for delivery and expression of 
siRNA, BV-H1-siLuc with an shRNA against the firefly luciferase reporter gene 
and BV-CMV-Luc with the luciferase reporter gene, were first used for 
co-transduction of human NT2 cells at a viral MOI of 200. Co-transduction of 
BV-CMV-eGFP and BV-CMV-Luc was served as a control to indicate 
transduction efficiency. RT-PCR analysis demonstrated that the luciferase 
mRNA decreased upon the infection of BV-H1-siLuc (Fig. 15A). We used BLI 
to continuously monitor the luciferase expression on infected NT2 cells at 24 
and 48 hours after transduction. As indicated in Fig. 15B, BV-H1-siLuc 
significantly inhibited expression of luciferase from BV-CMV-Luc at both time 
points. 
We further evaluated whether the incorporation of CMV enhancer in the 
expression cassette will improve the siRNA expression controlled by H1 
promoter and thus enhance the silencing effects (Fig. 16 & Fig. 17). NT2 and 
C6 cells seeded in a 24-well plate were infected with BV-CMV-Luc at an MOI of 
200 and allowed to express the luciferase report gene without interference for 
one day. The cells were then infected again with BV-H1-siLuc, BV-CMV 
E/H1-siLuc or BV-CMV-eGFP (as vector control) at the same MOI. The 
luciferase expression on the same wells were measured daily by BLI with the 
IVIS® imaging system. It was demonstrated that BV-H1-siLuc was able to 
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inhibit luciferase expression from BV-CMV-Luc in C6 cells at day 3 and in NT2 
cells at both day 2 and 3. The maximum inhibition at day 3 was 80% in C6 cells 
and 60% in NT2 cells relative to the viral vector control. After the incorporation 
of the CMV enhancer into the expression cassette, the gene silencing effects 
of the baculoviral vectors were enhanced. Firstly, the inhibition became 
effective earlier. While BV-H1-siLuc infection did not result in statistically 
significant decrease in luciferase expression in C6 cells at day 2, BV-CMV 
E/H1-siLuc infection led to 80% of inhibition in this cell line at the same time 
point. Secondly, the inhibition was more effective. At day 3, the inhibition 
increased statistically significantly from 80% provided by BV-H1-siLuc to 95% 
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Fig. 15 Baculovirus-mediated gene silencing effects in vitro. NT2 cells (3 x 104 cells 
per well in a 24-well plate) were co-infected with BV-CMV-Luc and BV-H1-siLuc or 
BV-CMV-eGFP (as a vector control), at an MOI of 200 each. (A) RT-PCR analysis. Two 
days after viral infection, cells were collected to extract total RNA. RT-PCR was carried 
out using specific primers for the luciferase gene and GAPDH gene. (B) Monitoring of 
luciferase expression in living NT2 cells with BLI. Bioluminescence signals were captured 
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Fig.16 Quantitative analyses of baculovirus-mediated gene silencing effects in C6 
cells. Cells were seeded at a density of 3 x 104 cells per well in a 24-well plate and 
infected with BV-CMV-Luc at a viral MOI of 200. Twenty-four hours after the first infection, 
the cells were infected with BV-H1-siLuc, BV-CMV E/H1-siLuc or BV-CMV-eGFP, at an 
MOI of 200. (A) Luciferase activities are expressed as photons per sec over time. Points, 
mean (n=4); bars, SD. (B) The data were first normalized with pre-infection samples and 
calculated as percentage of bioluminescence signals of test samples against control 
samples over time. Columns, mean (n = 4); bars, SD. +++, p<0.001 compared with BV 
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Fig. 17 Quantitative analyses of baculovirus-mediated gene silencing effects in NT2 
cells. Cells were seeded at a density of 3 x 104 cells per well in a 24-well plate and 
infected with BV-CMV-Luc at a viral MOI of 200. Twenty-four hours after the first infection, 
the cells were infected with BV-H1-siLuc, BV-CMV E/H1-siLuc or BV-CMV-eGFP, at an 
MOI of 200. (A) Luciferase activities are expressed as photons per sec over time. Points, 
mean (n=4); bars, SD. (B) The data were first normalized with pre-infection samples and 
calculated as percentage of bioluminescence signals of test samples against control 
samples over time. Columns, mean (n = 4); bars, SD. +++, p<0.001 compared with BV 
control; ** p<0.01 and *** p<0.001, compared with BV-H1-siLuc. 
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3.3.2 Knockdown of luciferase gene expression in rat brain 
Given the effective knockdown of the target gene in vitro, we next tested 
whether baculovirus-mediated siRNA expression was able to silence the target 
gene expression in vivo. We co-injected BV-CMV-Luc together with 
BV-H1-siLuc, BV-CMV E/H1-siLuc or the control vector BV-CMV-eGFP into the 
rat striatum. Two days after injection, rat brains were taken and dissected into 
three parts, the striatum, the cerebral cortex and the rest of the brain. 
Luciferase expression in each brain region was measured separately by 
luciferase activity assay. In the striatum, 60% reduction of the luciferase 
expression was achieved by BV-H1-siLuc and 82% reduction by BV-CMV 
E/H1-siLuc (Fig. 18). When results from the three parts of the brain were 
combined together, the overall reduction of luciferase expression was 50 and 
80% by BV-H1-siLuc and BV-CMV E/H1-siLuc, respectively (Fig. 18). The 
significant difference between the inhibitions induced by the two viral vectors 
indicated that, the in vivo gene silencing effects provided by the H1 construct 
could be improved by the CMV enhancer. These results are promising, in view 
of a recent study reporting the failure to induce RNA interference by direct 
injection of synthetic siRNA into the brain, despite the RNA silence effects were 
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(as a vector control), 
tissue samples were 
collected for luciferase 
activity assay. Four brain 
samples were used for 
each group. Values are 
expressed as RLU per 
tissue.  
+, p<0.05 and +++, 
P<0.001, respectively, 
compared with the 
control viral vector.  
*, p<0.05 compared with 
BV-H1-siLuc.  
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As a promising gene for cancer therapy, the DTA gene has shown its 
efficacy in many studies (Maxwell et al., 1986; Massuda et al., 1997; Li et al., 
2002; Ohana et al., 2002; Peng et al., 2002). This bacterial protein encoded by 
the DTA gene is highly toxic when introduced into the cytoplasm of eukaryotic 
cells. It inhibits protein synthesis by catalyzing ADP ribosylation of the 
diphthamide group of cellular elongation factor 2, and kills cells through an 
apoptosis pathway (Michl et al., 2004). Although so-called suicide gene 
therapy could also been accomplished by using other genes, such as HSV-tk 
followed by systemic administration of the prodrug GCV (Izquierdo et al., 1996), 
the efficacy of HSV-tk/GCV approach is often undermined by the blood brain 
barrier which make it difficult to achieve sufficient GCV concentration within the 
gliomas located in the brain. However, for DTA-based gene therapy, only 
minimal DTA expression is required to induce cell death in a cell cycle 
independent way, killing both dividing and non-dividing tumor cells (Rodriguez 
et al., 1998). 
 Due to the high toxicity of DTA in mammalian cells, its accurate targeting 
to tumor cells is necessary in order to avoid unintended deleterious effects on 
non-target cells, especially for the treatment of gliomas located in the 
vulnerable CNS. Glioma-specific gene expression could be realized by two 
strategies. The first one is to utilize the natural tropism of a delivery vector or to 
retarget the vectors by conjugating with glioma-specific ligand molecules (Van 
et al., 2002). The results of the current study have demonstrated that 
                             Chapter Four: Discussion and Conclusion 
- 70 - 
baculovirus was able to effectively transduce glioma cell lines in vitro (Fig. 1) 
and, in addition, the tropism of baculovirus towards glial cells, not the neuron 
cells, in brain was observed in previous studies (Sarkis et al., 2000; Li et al., 
2004). However, the tropism of vector per se is usually not enough and many 
factors will affect the targeting accuracy. Therefore, a tissue- or tumor-specific 
promoter has been used as another approach to ensure glioma targeting at the 
transcriptional level (Shinoura et al., 2000; Miyao et al., 1993). In the current 
study, a GFAP promoter was used to restrict the expression of DTA in glioma 
cells. In combination with the intra-tumor injection procedure, the use of the 
cell type-specific promoter could significantly reduce the risk of disturbing 
neuronal functions caused by the over-expression of the toxin gene. Although 
the expression of transgenes in astroglia , surrounding the boundary of the 
glioma might occur, this is less likely to cause severe adverse effects to the 
CNS, because the astroglia are not crucial for normal CNS function. 
Compared with the ubiquitous viral promoter, one major disadvantage of 
cellular promoters is their weak transcriptional activity, which results in low 
levels of transgene expression and affects their therapeutic efficacy. In order to 
overcome this problem, we modified the GFAP promoter by incorporating 
additional transcriptional regulatory elements. In the context of a baculoviral 
vector, the transcriptional activity of the GFAP promoter was enhanced by 
incorporating a CMV enhancer, and was further improved by adding AAV ITRs. 
We also demonstrated that the glial cell specificity of the GFAP promoter was 
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not impaired by this modification. The GFAP promoter is inactive in insect cells, 
as revealed by our observations that while a baculovirus with an eGFP gene 
driven by the viral CMV promoter produced green fluorescence in insect cells, 
the baculovirus using the GFAP promoter did not show any eGFP-positive 
insect cells. This cellular specificity has made it possible for us to produce high 
titer recombinant baculovirus containing the DTA gene. We have thus 
demonstrated the usefulness of the baculovirus/insect cell system to generate 
recombinant toxin gene-expressing viral vectors suitable for targeted toxin 
gene expression in tumor cells. The low levels of luciferase expression in two 
tested non-glioma cell lines and their resistance to BV-CG/ITR-DTA 
transduction further proved the glial cell specificity of this GFAP 
promoter-based expression cassette. Interestingly, our recombinant 
baculovirus accommodating the engineered expression cassette could 
achieve a higher level of transgene expression in the glioma cell-inoculated 
brain region than in the normal brain region. This could be explained by the 
active proliferation of tumor cells and/or gliosis in the surrounding regions in 
response to the damage caused by glioma invasion. The baculoviral vector 
created in the current study is a promising vector for glioma gene therapy and 
its performance in the treatment of gliomas will be further improved if an 
authentic glioma-specific promoter is employed to further increase the 
specificity and efficiency of this baculoviral vector. 
A rat C6 xenograft animal model was used in the current study, allowing 
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the non-invasive monitoring of tumor growth in vivo. High transduction 
efficiency (98%) was observed with C6 cells in vitro, when baculovirus with the 
CG/ITR expression cassette was used. Based on the high transduction 
efficiency and the potent effect of DTA, it is reasonable to observe a significant 
inhibition of C6 cell growth in animal model (Fig. 3C & D). The failure to 
eliminate more C6 cells in the in vivo study is mainly due to the poor diffusion 
of injected baculovirus within the tumor mass. Therefore, it is possible to 
further improve the inhibition of C6 glioma growth by multiple injections of 
viruses into several sites of the glioma tumor. 
The success of RNAi-based gene therapy also relies greatly on the 
development of vectors, especially on the choice of expression cassette that 
controls shRNA expression. Pol III promoters are distinguished by their high 
transcriptional activity, which is able to provide approximately 4 x 105 
transcripts per cell (Matthess et al., 2005). However, in certain circumstances, 
the activities of the original Pol III promoters are not sufficient to provide 
satisfactory gene silencing outcomes (Ilves et al., 1996; Boden et al., 2003; 
Thompson et al., 1995; Paul et al., 2002; Xia et al., 2003). To enhance the 
transcriptional activity and improve the knockdown of target gene expression, 
a hybrid promoter was created in the current study by fusing the CMV 
enhancer 5’ to the H1 promoter. Our findings are consistent with those from a 
previous study in which the CMV enhancer was fused to the U6 promoter (Xia 
et al., 2003). Both the H1 and U6 promoters are type III Pol III promoters and 
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are located only in the 5’-flanking region of the genes transcribed by them. This 
gene-external feature resembles that of Pol II promoters but differs 
significantly from that of types I and II of Pol III promoters, which are located 
entirely within the transcribed region. While the Pol III U6 promoter directs the 
synthesis of the U6 snRNA, Pol II promoters are used for transcription of the 
U1 to U5 snRNAs. Strikingly, not only is the spatial organization of the U6 
promoter elements similar to that of the U2 elements, they also share 
homologous sequence in the enhancer, as well as in the PSE, which functions 
like a TATA box (Hernandez, 2001). Competition experiments further showed 
that the enhancers of the two promoters bind to common transcription factors 
in vivo and in vitro (Carbon et al., 1987). These findings from the snRNA 
promoters have led to the concept that common factors are shared by the Pol 
II and III transcription machineries. The results of the current study using the 
H1 promoter demonstrate that a RNA polymerase II enhancer is able to 
enhance transcriptional activity of a RNA polymerase III promoter. An effective 
knockdown of the luciferase reporter gene expression was demonstrated in 
the current study, indicating the feasibility of using recombinant baculovirus 
with engineered expression cassette as a delivery vector for RNA i. Since this 
“proof of concept” study is based on the knockdown of a reporter gene, in 
future, studies based on RNAi targeting aberrantly overexpressed genes, for 
example, EGFR, VEGF, telomerase, or leptin (Kang et al., 2006; Saydam et al., 
2005; Tao et al., 2005; Pallini et al., 2006; Brown et al., 2005) would be 
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necessary to further explore the feasibility of baculovirus-mediated RNAi for 
gioma therapy. 
 Owing to their high transduction efficiency in vitro and in vivo, viral vectors 
such as retrovirus and adenovirus are predominantly used in the glioma gene 
therapy (Gomez-Manzano et al., 2004; Pulkkanen et al., 2005). However, 
endogenous virus recombination, insertional mutagenesis, pre-existing 
immune response and limited DNA-carrying capacity remain notorious 
shortcomings of these viral vectors. The application of retrovirus vectors is 
further hindered by the disadvantages such as low virus titer and instability of 
the virion (Ram et al., 1997). For adenovirus, although several harmful 
non-essential viral genes have been deleted, the strong immune response 
caused by this virus still restricts its application, especially in human clinical 
trials. Being able to overcome these practical limitations to some extent, 
baculoviral vectors are attractive alternative vectors for gene therapy. A 
tropism toward glial cells but not toward neurons has been demonstrated in 
vivo and according to the results of the current study, this cell type specificity 
could be enhanced by the use of a cell type-specific expression cassette. In 
addition, most baculoviral vectors stay episomally in the nucleus and can thus 
mediate only transient gene expression, which is suitable for cancer gene 
therapy requiring short-term therapeutic gene expression. In terms of 
transduction efficiency, baculoviral vectors tested in the current study are quite 
comparable to other commonly used viral vectors, such as adeno-associated 
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virus (AAV), adenoviruses, and lentivirus. As demonstrated in one recent study, 
AAV2 was able to transduce up to 80% of cells at an MOI of 5,000, and 90% at 
an MOI of 50,000 in five human glioma cell lines (Huszthy et al., 2005). In 
another study (Enger et al., 2002), six glioma cell lines have been transduced 
with AAV2 and adenovirus carrying GFP at an MOI of 100 and results showed 
various transduction efficiencies in different cell lines, ranging from 1.5% to 
81%, with most of the values being less than 50%. Transduction efficiency 
from 50% to 90% in U87 glioma cells has been obtained with lentiviral vectors 
at an MOI of 1 (Steffens et al., 2004). Furthermore, the large cloning capacity 
of baculovirus makes it possible to incorporate several therapeutic genes 
towards multiple therapeutic targets into a single baculoviral vector. Thus 
baculoviral vectors provide a highly appealing possibility to improve the 
therapeutic effects by using a combination of synergic therapeutic genes 
based on different mechanisms. For example, we could incorporate an 
expression cassette of the DTA gene and that of shRNA targeting EGFR into 
one single baculoviral vector and thus inhibit the tumor growth synergistically. 
In conclusion, a new type of recombinant baculoviral vector has been 
developed by incorporating engineered regulatory elements. Its ability to 
knockdown target gene expression was demonstrated both in vitro and in vivo; 
hence it provides a potential therapeutic approach to knock down 
disease-related genes. In addition, a baculoviral vector carrying a toxin gene 
has been developed which could effectively inhibit glioma cell growth. To the 
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best of our knowledge, this study is the first demonstration of the use of 
baculovirus as a vector for cancer gene therapy in an animal model. It will 
provide valuable knowledge for potential human clinical trials. Because of the 
unsatisfactory outcomes of glioma gene therapy in clinical trials, it is necessary 
to develop efficient and safe vectors that could be applied in the clinical setting. 
In addition, the combination of suicide gene therapy with other approaches 
such as immunotherapy, RNAi-based approaches, and/or conventional 
treatments (e.g., surgery or chemotherapy) might be a more effective strategy 
for glioma treatment. 
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